SCHOTT Pharma AG & Co. KGaA

1SXP

Equity

ISIN DE000A3ENQ51 / Valor 128964250

Xetra (2025-12-19)

EUR 14.82-0.27%

SCHOTT Pharma AG & Co. KGaA
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

SCHOTT Pharma AG & Co. KGaA, a subsidiary of SCHOTT AG, specializes in the production of drug containment and delivery systems, including pharmaceutical syringes, cartridges, vials, and ampoules. With a global presence in 34 countries and 16 GMP-compliant manufacturing sites, the company produces over 13 billion drug containers annually, catering to the needs of the pharmaceutical industry. Employing more than 4,700 professionals across North America, Europe, Asia, and Latin America, SCHOTT Pharma collaborates with leading industry partners to ensure the safe, fast, and reliable delivery of medicines. The company operates under the ownership of the Carl Zeiss Foundation and is headquartered in Mainz, Germany. In the fiscal year 2021, SCHOTT Pharma contributed to SCHOTT AG's overall sales of 2.5 billion euros, leveraging its expertise in borosilicate glass and high-grade pharmaceutical COC polymer to meet diverse drug formulation requirements.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue and growth

Q3 2025 revenues: EUR 256m (Q3 2024: EUR 254m). Reported growth +1% year‑on‑year, driven by +3% organic growth partly offset by -2% FX effects.

Profitability

EBITDA rose to EUR 83m (Q3 2024: EUR 74m) with an EBITDA margin of 32.4% (29.4% prior year). EBIT increased to EUR 63m (margin 24.7% vs 22.9% prior year).

Net income and EPS

Profit for the period was EUR 46m (unchanged vs Q3 2024). Reported EPS was EUR 0.30 (Q3 2024: EUR 0.31).

Cash flow and balance sheet

Operating cash flow: EUR 55m (Q3 2024: EUR 58m). Cash flow from investing: EUR -38m (vs -24m). Free cash flow: EUR 17m (vs 34m). Net debt stood at EUR 116m (Q3 2024: 119m) and equity ratio improved to 56.6% (54.9% prior year).

Segment performance — Drug Containment Solutions (DCS)

DCS revenues EUR 142m (Q3 2024: 137m). EBITDA increased to EUR 38m (Q3 2024: 30m), lifting the segment EBITDA margin to 26.8% (21.8% prior year). EBIT improved to EUR 29m (20.4% margin).

Segment performance — Drug Delivery Systems (DDS)

DDS revenues EUR 116m (Q3 2024: 114m). EBITDA slightly decreased to EUR 42m (43m prior year) and EBITDA margin was 36.9% (37.1% prior year). EBIT declined to EUR 32m (27.8% margin).

Working capital, headcount and operational notes

Working capital increased to EUR 207m (Q3 2024: 175m), raising the working capital ratio to 21.2% of revenues (18.3% prior year). Headcount increased to 4,775 (4,690 at 30.09.2024).

9‑month (9M) snapshot

9M 2025 (01.10.2024–30.06.2025): Revenues EUR 739m (9M 2024: 720m), EBITDA EUR 213m (191m), EBIT EUR 156m (144m). Profit for the period EUR 113m (116m) and 9M EPS EUR 0.75 (0.77).

Summarized from source with an LLMView Source

Key figures

-38.4%1Y

%3Y

%5Y

Performance

37.3%1Y

38.8%3Y

38.8%5Y

Volatility